Provided by Tiger Fintech (Singapore) Pte. Ltd.

Leap Therapeutics Inc

0.2616
-0.0181-6.47%
Post-market: 0.26990.0083+3.17%19:47 EDT
Volume:1.02M
Turnover:286.19K
Market Cap:10.84M
PE:-0.15
High:0.2914
Open:0.2750
Low:0.2616
Close:0.2797
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, Eli Lilly, Nuclear stocks

Reuters
·
23 Jun

BRIEF-Leap Therapeutics Reports Updated Clinical Data From Sirexatamab Colorectal Cancer Study

Reuters
·
23 Jun

Leap Therapeutics Inc - to Explore Sale or Partnership for Sirexatamab and Fl-501

THOMSON REUTERS
·
23 Jun

Leap Therapeutics Inc - Estimates $3.2 Mln Cost for Workforce Reduction

THOMSON REUTERS
·
23 Jun

Leap Therapeutics Reports Updated Clinical Data From Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

THOMSON REUTERS
·
23 Jun

Leap Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BRIEF-Leap Therapeutics Q1 Net Income USD -15.435 Million

Reuters
·
13 May

BRIEF-Leap Therapeutics - Announces 50% Workforce Reduction In Strategic Restructuring - SEC Filing

Reuters
·
13 May

Leap Therapeutics Inc - Announces 50% Workforce Reduction in Strategic Restructuring - SEC Filing

THOMSON REUTERS
·
13 May

Leap Therapeutics - Q1 Loss per Share $0.37

THOMSON REUTERS
·
13 May

Leap Therapeutics Reports Q1 2025 Net Loss of $15.4M, Up from $13.8M in Q1 2024, Due to Increased R&D Expenses

Reuters
·
13 May

Leap Therapeutics Q1 EPS USD -0.37

THOMSON REUTERS
·
13 May

Leap Therapeutics Inc: Has Reduced Its Workforce by Approximately 50%

THOMSON REUTERS
·
13 May

Leap Therapeutics Inc: Strategic Restructuring to Prioritize Clinical Focus on Development of Sirexatamab in Crc

THOMSON REUTERS
·
13 May

Leap Therapeutics Q1 Operating Expenses USD 15.917 Million

THOMSON REUTERS
·
13 May

Leap Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
09 May

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

PR Newswire
·
26 Apr

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

PR Newswire
·
15 Apr

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Benzinga
·
27 Mar

Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial

MT Newswires Live
·
26 Mar